What is the history of Sjögren-Larsson Syndrome?

Sjögren-Larsson Syndrome was first described in 1957 by Swedish physicians Torsten Sjögren and Tage Larsson, who identified a unique triad of congenital ichthyosis, intellectual disability, and spasticity. Since its discovery, medical understanding has evolved from a purely clinical observation to a well-characterized metabolic disorder caused by mutations in the ALDH3A2 gene, allowing for precise molecular diagnosis and improved supportive care.

How was Sjögren-Larsson Syndrome first discovered?

The history of Sjögren-Larsson Syndrome began in northern Sweden, where researchers observed a cluster of families exhibiting a rare combination of symptoms. Torsten Sjögren, a psychiatrist, and Tage Larsson, a mathematician and actuary, conducted an exhaustive epidemiological study of the region. They published their findings in 1957, establishing Sjögren-Larsson Syndrome as a distinct clinical entity inherited in an autosomal recessive pattern.

How has our understanding of the condition evolved?

For decades, physicians relied solely on clinical symptoms to diagnose Sjögren-Larsson Syndrome. The most significant shift occurred in 1996, when researchers identified that the syndrome is caused by a deficiency of the enzyme fatty aldehyde dehydrogenase (FALDH). This discovery shifted the focus from symptomatic management to understanding the biochemical pathway of long-chain fatty alcohol oxidation. Today, Sjögren-Larsson Syndrome is known to stem from mutations in the ALDH3A2 gene, which leads to the toxic accumulation of fatty aldehydes in tissues.

What are the major milestones in the history of the disease?

• 1957: First clinical description of Sjögren-Larsson Syndrome by Sjögren and Larsson.


• 1996: Identification of the ALDH3A2 gene as the underlying cause.


• Modern Era: Development of diagnostic genetic testing and the establishment of patient registries, including the 14 members currently sharing their experiences on DiseaseMaps.org.

How have technology and advocacy changed the patient experience?

Historically, families affected by Sjögren-Larsson Syndrome often faced isolation due to the rarity of the condition. The advent of molecular genetics has replaced the need for subjective clinical observation with definitive testing. Furthermore, patient advocacy groups and digital platforms like DiseaseMaps.org have empowered those living with Sjögren-Larsson Syndrome to connect, share data, and participate in clinical research, moving the community from passive observation to active partnership with the scientific community.

Next steps

• Consult a clinical geneticist to review potential genetic testing options.


• Connect with the 14 community members on DiseaseMaps.org to share insights and lived experiences.


• Review the latest clinical literature via the NIH GARD portal to stay informed on current management protocols.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Sjögren-Larsson Syndrome.


• OMIM (Online Mendelian Inheritance in Man): Entry #270200.


• Orphanet: Rare Disease Database (ORPHA:3197).